Progression-free survival: Too much risk, not enough reward?

Neuro-Oncology

Volumn 16, Issue 5, 2014, Pages 615-616

  Alexander, Brian M ^a   Trippa, Lorenzo ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

CANCER GROWTH; CANCER SURVIVAL; CORRELATION ANALYSIS; EDITORIAL; GLIOBLASTOMA; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SELECTION BIAS; SURVIVAL TIME; TUMOR RECURRENCE; MORTALITY;

GLIOBLASTOMA; HUMANS;

EID: 84899420619     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou041     Document Type: Editorial

References (7)

1. Han K Ren M Wick W et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: A literature-based meta-Analysis from 91 trials. Neuro Oncol. 2014;16:696-706
2. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. 1989;8:431-440
3. Stupp R Hegi ME Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466
4. Broglio KR Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101: 1642-1649
5. Gilbert MR Dignam JJ Armstrong TS et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708
6. Chinot OL Wick W Mason W et al. Bevacizumab plus radiotherapy- Temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):709-722
7. Terasaki M Murotani K Narita Y et al. Controversies in Clinical Trials of Cancer Vaccines for Glioblastoma. J Vaccines Vaccin. 2013;4:2.